Journal of Cosmetic Dermatology最新文献

Background: Refractory rosacea can be effectively treated with fractional microneedle radiofrequency (FMR), but its optimal parameters need confirmation.

Objective: To explore the optimal parameters of FMR in treating rosacea-like dermatitis and the underlying mechanisms.

Methods: A rosacea-like dermatitis mouse model was intervened with FMR of varying pulse energy and width. By assessing the severity of erythema and measuring erythema area, optimal parameters of FMR to treat rosacea-like dermatitis in mice were determined. Pathological staining was performed to examine the infiltration of inflammatory cells and CD31⁺ microvessels. Expression levels of pro-inflammatory factors were detected by qRT-PCR. The involvement of the NF-κB signaling pathway and its downstream mediators (IL-1β, IL-6, TNF-α) in mice treated with low-power short-pulse-width fractional microneedle radiofrequency (LS-FMR) was detected using Western blotting. In a cohort of 20 patients with erythematotelangiectatic rosacea (ETR) and managed by one session of FMR treatment, therapeutic efficacy was assessed by Multispectral skin analysis system at 3 months of follow-up.

Results: LS-FMR at energy levels of 1, 2, 3 and 4 W and pulse width of 20 ms alleviated the severity of erythema and narrowed the erythema area in LL37-induced mice. It significantly inhibited the infiltration of mast cells and CD4+ T cells, polarization of CD4+ T cells to Th1/Th17 cells, angiogenesis, the activation of the NF-κB signaling pathway, as well as the expression of downstream inflammatory cytokines (IL-1β, IL-6, TNF-α). In a cohort of 20 ETR patients, just one session of FMR treatment significantly alleviated erythema at 3 months of follow-up, without obvious adverse events.

Conclusion: LS-FMR is a promising approach to treat rosacea by suppressing skin immune responses and angiogenesis.

Trial registration: Clinical trial number: Not applicable.

Introduction: The use of hyaluronic acid (HA) fillers is rising globally. Traditionally, the rheology of HA fillers has been subject to investigations for their use in facial soft tissues. Hitherto, there has been a significant gap in understanding their rheologic properties in body applications. The requirements for body fillers are different from facial fillers as they are applied for larger volume deficits, and experience greater mechanical stress. This study aims to fill this gap by analyzing the physicochemical and rheological properties of HA body fillers to guide clinical practice.

Materials and methods: Four commercially available HA-based body fillers were analyzed under standardized laboratory conditions. The physicochemical properties, including pH, osmolality, ion concentrations, clarity, and swelling factor, were assessed. Rheological properties, including storage modulus (G'), loss modulus (G″), complex modulus (G*), and tan delta (tan δ), were assessed between 0.1 and 1 Hz.

Results: The physicochemical analysis revealed no significant differences among the fillers, indicating uniform chemical stability. However, rheological analysis showed significant variations. Infini B Body exhibited the lowest G', G″, and G* values. In contrast, HYAcorp MLF1 and MLF2 displayed higher G' and G* values, indicating greater elasticity and stiffness. Consistent rankings between 0.1 and 1 Hz suggest stable mechanical performance under dynamic and sustained loading, supporting their suitability for high-load applications such as gluteal augmentation.

Conclusion: Selecting HA body fillers based on their rheological properties is crucial for optimizing outcomes, particularly in body contouring procedures where mechanical demands differ from those of facial applications. Clinicians should tailor filler selection to the specific requirements of each body area. Further research is required to validate these findings in long-term clinical settings.

Background: Oily skin is characterized by excessive sebum production and increased activity of Cutibacterium acnes.

Aims: To evaluate the effects of mandelic acid exfoliation, microneedle mesotherapy with a sebum-regulating ampoule, and combination therapy on skin parameters and C. acnes activity in women with oily skin.

Methods: Fifty-five women aged 18-47 were randomly assigned to three groups: microneedle mesotherapy (6 treatments), mandelic acid exfoliation (6 treatments), or combination therapy (3 exfoliations followed by 3 mesotherapy treatments). Skin hydration, sebum level, pH, and gloss were measured using an MPA Courage&Khazaka device. C. acnes activity was assessed indirectly by porphyrin fluorescence with a Visiopor device. Measurements were taken on the cheeks and in the T-zone before treatment (day 1), after three session (day 63), and after six sessions (day 126).

Results: Skin hydration increased significantly in all groups. Mesotherapy reduced sebum in the T-zone only after six treatments, while exfoliation reduced sebum mainly on the cheeks. Combination therapy resulted in the most extensive and stable sebum reduction in both areas. A temporary decrease in pH was observed after mesotherapy, with no pH changes after exfoliation or combination therapy. No significant changes in skin gloss were found. C. acnes colonization increased in the T-zone after mesotherapy, whereas exfoliation and combination therapy significantly reduced all colonization indices, with the strongest effect for combination therapy.

Conclusions: Mandelic acid exfoliation and microneedle mesotherapy support regulation of sebaceous activity and epidermal barrier function. Combination therapy is therapeutically superior, providing optimal improvement in skin parameters and the most effective reduction of C. acnes activity.

Background: Botulinum toxin is widely used for aesthetic and functional indications and is generally considered safe; however, post-procedural headache remains a recognized but underexplored adverse effect, particularly in cosmetic practice.

Objective: To evaluate the incidence, characteristics, and potential risk factors of headache following botulinum toxin injections administered to different anatomical regions.

Methods: This prospective observational study included 102 adult patients undergoing abobotulinumtoxinA injections to the upper facial regions, masseter muscles, and/or axillary area. Headache occurrence was assessed on day 3 by telephone, at days 10-12 during follow-up visits, and through patient-initiated contact within the first month. Demographic variables, prior botulinum toxin exposure, injection-related pain, toxin dose, and headache characteristics were recorded.

Results: Post-botulinum headache occurred in 13 patients (12.7%) and was generally mild-to-moderate, short-lived, and self-limited. Headache was significantly more frequent in first-time recipients compared with previously treated patients (45.5% vs. 8.8%, p = 0.005). All patients who developed headache had received injections involving the upper facial regions, whereas no headache was observed after exclusive masseter or axillary treatments. No associations were found with toxin dose, procedural pain, or systemic comorbidities.

Conclusion: Post-botulinum headache is an infrequent, benign, and transient event, predominantly affecting first-time patients undergoing upper facial injections. These findings may aid clinicians in patient counseling and expectation management.